UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 22, 2010
OCEAN BIO-CHEM, INC.
(Exact name of registrant as specified in charter)
Florida 0-11102 59-1564329
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
4041 S.W. 47 Avenue, Fort Lauderdale, Florida 33314
(Address of principal executive office Zip Code)
(954) 587-6280
Registrant's telephone number,
including area code:
Not Applicable
(Former name or former address, if changes since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ]Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[]Soliciting material pursuant to Rule l4a-l2 under the Exchange Act (17
CFR 240.14a-12)
[ ]Pre-commencement communications pursuant to Rule l4d-2 (b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.l3e-4(c))
Item 7.01 Regulation FD
On January 20, 2010, the Company issued a press release announcing its
intent to enter a joint venture to expand into a new group of products using
chlorine-dioxide with a patented delivery system. The full text of the press
release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In
connection with this strategy, the Company entered into a Letter of Intent with
BBL Distributing, Inc. dated of January 19, 2010 The information contained in
the press release attached as Exhibit 99.1 to this Current Report on Form 8-K
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject
to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description of Exhibit
99.1 Press release, dated January 20, 2010, announcing Registrant's plans
to begin manufacturing, marketing and distributing chlorine dioxide based
products.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OCEAN BIO-CHEM, INC.
Date: January 22, 2010 By: /s/ Jeffrey S. Barocas
----------------------------------
Jeffrey S. Barocas
Chief Financial Officer
Exhibit 99.1
January 20, 2010
Ocean Bio-Chem, Inc. Announces Letter of Intent to form a Joint Venture
ODOR STAR TECHNOLOGY LLC.
FORT LAUDERDALE, FL--(Marketwire January 20, 2010) - Ocean Bio-Chem, Inc.
(NASDAQ: OBCI) announced today the signing of a Letter of Intent to form a new
joint venture, Odor Star Technology LLC (OST).
Ocean Bio-Chem. President and CEO Peter Dornau commented, "The Company" has
signed a letter of intent to form a joint venture for a group of products that
utilizes a unique, patented formula and delivery system to safely kill mold,
mildew, bacteria and viruses. This group of new products use a powerful, yet
safe, EPA approved antimicrobial technology known as Chlorine Dioxide (CLO2).
While CLO2 has been used successfully for years the technology was not available
to consumers and many industries due to the cost of generating the CLO2. Our
patented delivery system allows us to precisely control the release rates of the
product and develop a number of consumer and industrial products at a reasonable
cost. Additional uses, are as a pathogenic control to purify water (Versan),
algaecide for the elimination of noxious odors and, sanitizing of solid surfaces
(Avanflex) as well as air purification (NosGUARD) in enclosed spaces. The sales
potential of these products are large due to the applicability to an extremely
broad range of industries, from marine to household, industrial, medical,
hospitality, food preparation, farm and more. This group of products brings the
ability to disinfect homes and eliminate mold issues and smells, to health care
facilities or any enclosed structure from odor and pathogenic contamination. The
product application is especially effective for any shared public spaces. These
products will be integrated into the existing Star brite product line and is
expected to result in increased sales and distribution to the Company's current
customers in the marine market. As noted, these products also have many
applications beyond those related to boats, allowing the Company to enter
numerous huge new markets. The products are proven safe for use around people
and animals."
Peter Dornau continued "The new company, OST, is being formed as a 50/50
joint venture with BBL Distributing, Inc. The joint venture will consolidate all
intangible intellectual property for these products to include patents,
trademarks, formulas and copyrights. Additionally, EPA regulatory registrations
will be transferred into the joint venture. OST will have several patents in the
United States, and will patent in Canada and Europe. OST will also license the
technology to other companies in markets that we choose not to market in,
creating additional royalty income."
Peter Dornau concluded, "Production, operations and quality control are up
and running at our wholly-owned subsidiary, Kinpak, Inc. We are in the final
stages of finalizing agreements, due diligence and contracts. We are very
excited about the potential and positive impact these products will have on the
Company's future financial results."
About Ocean Bio-Chem
Ocean Bio-Chem, Inc. manufactures and markets a full line of maintenance
and care products for boats, recreational vehicles, automobiles, motorcycles and
aircraft. Products are sold under the Starbrite name. The Company trades
publicly under NASDAQ SmalICap Ticker Symbol: OBCI.
The Company's web sites are: www.oceanbiochem.com, www.starbrite.com and
www.startron.com.
For additional information contact:
Peter Dornau peter@starbrite.com or: Jeff Barocas jbarocas@starbrite.com
(954) 587-6280 (954) 587-6280
President and CEO, Ocean Bio-Chem, Inc. Chief Financial Officer.
Ocean Bio-Chem, Inc.
NOTE: The foregoing is news relating to Ocean Bio-Chem, Inc. (OBCI or "the
Company") and contains forward-looking statements, which are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995.
The forward-looking statements Involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking statements.
When used in this report, the words "anticipate," "believe," "estimate,"
"expect" and similar expressions as they relate to the Company or its
management, including without limitation the Company's other subsidiaries, are
intended to identify such forward-looking statements. The Company's actual
results, performance or achievements could differ materially from the results
expressed in, or implied by these forward-looking statements. For more detailed
information the reader is referred to the Company's 10-K and other documents
filed with the United States Securities and Exchange Commission.
